David S Hong

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors
    D S Hong
    University of Texas M D Anderson Cancer Center, Unit 455, PO Box 301402, Houston, TX, 77030, USA
    Invest New Drugs 32:436-44. 2014
  2. ncbi request reprint A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma
    David S Hong
    Division of Cancer Medicine, Department of Investigational Cancer Therapeutics, University of Texas M D Anderson Cancer Center, Houston, TX Electronic address
    Clin Genitourin Cancer 12:167-177.e2. 2014
  3. ncbi request reprint MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study
    David S Hong
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, MD Anderson Cancer Center, Houston TX, USA Electronic address
    Lancet Oncol 15:656-66. 2014
  4. pmc Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors
    David Hong
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 19:4824-31. 2013
  5. doi request reprint A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors
    David S Hong
    Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Invest New Drugs 31:918-26. 2013
  6. doi request reprint Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy
    David S Hong
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Cancer Res Clin Oncol 139:963-70. 2013
  7. doi request reprint Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions
    David S Hong
    Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer Treat Rev 39:375-87. 2013
  8. doi request reprint Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience
    David S Hong
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Colorectal Cancer 11:297-303. 2012
  9. doi request reprint A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas
    David S Hong
    Department ofInvestigational Cancer Therapeutics, Phase I Clinical Trials Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:3396-406. 2012
  10. doi request reprint BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency
    David S Hong
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:2326-35. 2012

Detail Information

Publications72

  1. ncbi request reprint A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors
    D S Hong
    University of Texas M D Anderson Cancer Center, Unit 455, PO Box 301402, Houston, TX, 77030, USA
    Invest New Drugs 32:436-44. 2014
    ..The best tumor response was stable disease in eight patients. E7107 is a unique first-in-class molecule. The incidence of two cases of vision loss probably related to E7107 led to study discontinuation...
  2. ncbi request reprint A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma
    David S Hong
    Division of Cancer Medicine, Department of Investigational Cancer Therapeutics, University of Texas M D Anderson Cancer Center, Houston, TX Electronic address
    Clin Genitourin Cancer 12:167-177.e2. 2014
    ..Trebananib, an investigational peptibody, binds to angiopoietin 1 and 2, thereby blocking their interaction with Tie2...
  3. ncbi request reprint MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study
    David S Hong
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, MD Anderson Cancer Center, Houston TX, USA Electronic address
    Lancet Oncol 15:656-66. 2014
    ..We aimed to assess the safety and tolerability of MABp1 for interleukin-1α blockade in a refractory cancer population...
  4. pmc Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors
    David Hong
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 19:4824-31. 2013
    ..We conducted a phase I dose-finding and pharmacokinetic/pharmacodynamic study of BIIB028, a prodrug designed to inhibit Hsp90 activity...
  5. doi request reprint A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors
    David S Hong
    Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Invest New Drugs 31:918-26. 2013
    ..Dasatinib has been shown preclinically to overcome resistance to gemcitabine. We evaluated the safety and biological activity of the combination of dasatinib and gemcitabine in patients with advanced solid tumors...
  6. doi request reprint Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy
    David S Hong
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Cancer Res Clin Oncol 139:963-70. 2013
    ..The purpose of this study was to identify factors related to patients' willingness to provide study-related tumor biopsies in phase 1 clinical trials of molecularly targeted therapy...
  7. doi request reprint Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions
    David S Hong
    Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer Treat Rev 39:375-87. 2013
    ..We also discuss lessons learned from completed clinical trials of HSP90 inhibitors, and future directions for these promising therapeutic agents...
  8. doi request reprint Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience
    David S Hong
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Colorectal Cancer 11:297-303. 2012
    ..Patients with advanced colorectal cancer have a poor prognosis once standard therapies fail. This retrospective study presents the characteristics and outcomes in 144 patients treated in phase I clinical trials...
  9. doi request reprint A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas
    David S Hong
    Department ofInvestigational Cancer Therapeutics, Phase I Clinical Trials Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:3396-406. 2012
    ....
  10. doi request reprint BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency
    David S Hong
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:2326-35. 2012
    ..We carried out peripheral blood immunomonitoring before and following one or two 28-day cycles of treatment...
  11. ncbi request reprint Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors
    David S Hong
    Department of Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 107:1383-90. 2006
    ....
  12. doi request reprint A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer
    David S Hong
    Clinical Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 17:6582-91. 2011
    ..This phase I study sought an appropriate LY2275796 dose in patients with advanced tumors...
  13. pmc Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies
    David S Hong
    Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 96:997-1005. 2011
    ..We tested sorafenib, a B-Raf, RET, and vascular endothelial growth factor receptor kinase inhibitor, combined with tipifarnib, a farnesyltransferase inhibitor that inactivates Ras and other farnesylated proteins...
  14. pmc Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies
    David S Hong
    Division of Cancer Medicine, Department of Investigational Therapeutics Phase 1 Program, Unit 455, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 15:7061-8. 2009
    ....
  15. ncbi request reprint Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib
    David S Hong
    Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455, Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Arch Dermatol 144:779-82. 2008
    ....
  16. doi request reprint Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib
    David Hong
    Department of Investigational Therapeutics Phase I Program, Unit 455, Division of Cancer Medicine, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 7:1001-6. 2008
    ....
  17. pmc PIK3CA mutations in advanced cancers: characteristics and outcomes
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Oncotarget 3:1566-75. 2012
    ..PIK3CA mutations, especially, H1047R, were associated with attaining a PR/CR to PI3K/AKT/mTOR pathway inhibitors...
  18. pmc Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials
    Ishwaria M Subbiah
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 4:153-62. 2013
    ..Patients with advanced cholangiocarcinoma (CC) and gallbladder carcinoma (GC) have few therapeutic options for relapsed disease...
  19. doi request reprint Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center
    Ignacio Garrido-Laguna
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:1422-8. 2012
    ....
  20. doi request reprint Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative
    Apostolia Maria Tsimberidou
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:6373-83. 2012
    ..We initiated a personalized medicine program in the context of early clinical trials, using targeted agents matched with tumor molecular aberrations. Herein, we report our observations...
  21. pmc KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors
    Ignacio Garrido-Laguna
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 7:e38033. 2012
    ..To evaluate clinicopathologic and molecular features of patients with metastatic colorectal cancer (mCRC) and their outcomes in early-phase trials using pathway-targeting agents...
  22. pmc PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 73:276-84. 2013
    ..6, 95% confidence interval (CI), 1.02-43.0, P = 0.047). Our data suggest that interaction between PIK3CA mutation H1047R versus other aberrations and response to PI3K/AKT/mTOR axis inhibitors warrants further exploration...
  23. pmc PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e22769. 2011
    ..Oncogenic mutations of PIK3CA, RAS (KRAS, NRAS), and BRAF have been identified in various malignancies, and activate the PI3K/AKT/mTOR and RAS/RAF/MEK pathways, respectively. Both pathways are critical drivers of tumorigenesis...
  24. pmc PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
    Filip Janku
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 30:777-82. 2012
    ..Concomitant mutations in the mitogen-activated protein kinase (MAPK) pathway may mediate resistance...
  25. ncbi request reprint Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations
    Jennifer J Wheler
    Corresponding Author Jennifer Wheler, The University of Texas MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, Unit 455, 1400 Holcombe Boulevard, Houston, TX 77030
    Mol Cancer Ther 12:2167-75. 2013
    ..This combination warrants further study in select populations of non-small cell lung cancer...
  26. ncbi request reprint Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers
    Jennifer J Wheler
    Department of Investigational Cancer Therapeutics Phase I Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer Chemother Pharmacol 73:495-501. 2014
    ..We conducted a phase I study of the combination of the anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers...
  27. pmc Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer
    Gerald S Falchook
    Department of Investigational Cancer Therapeutics Phase I Program, U T MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 4:118-27. 2013
    ..Preclinical data indicate EGFR signals through both kinase-dependent and independent pathways and that combining a small-molecule EGFR inhibitor, EGFR antibody, and/or anti-angiogenic agent is synergistic in animal models...
  28. pmc Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic
    Filip Janku
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncologist 16:327-35. 2011
    ..The outcomes of patients with advanced non-small cell lung cancer (NSCLC) treated in phase I clinical trials have not been systematically analyzed...
  29. pmc P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy
    Rabin Said
    Phase I Clinical Trials Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 4:705-14. 2013
    ..Mutations in the p53 gene are amongst the most frequent aberrations seen in human cancer. Our objective was to characterize the clinical characteristics associated with p53 mutation in patients with advanced cancer...
  30. ncbi request reprint Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway
    Jennifer J Wheler
    Department of Investigational Cancer Therapeutics Phase I Program, The University of Texas MD Anderson Cancer Center, Houston, TX
    Oncotarget 5:3029-38. 2014
    ..Responses were observed in patients with multiple molecular aberrations. Clinical Trails Included: NCT01197170. ..
  31. ncbi request reprint Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA Electronic address
    Cell Rep 6:377-87. 2014
    ..This work provides further important clinical validation for continued and accelerated use of biomarker-driven trials incorporating rational drug combinations...
  32. pmc Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib
    Gerald S Falchook
    Division of Cancer Medicine, Departmentof Investigational Cancer Therapeutics, Phase I Clinical Trials Program, MD Anderson Cancer Center, Houston, TX 77030, USA
    JAMA Dermatol 149:322-6. 2013
    ..We report what we believe to be the first case in which Merkel cell polyomavirus (MCPyV) and human papillomavirus subtype 17 (HPV-17) were associated with cutaneous SCC that developed during treatment with the BRAF inhibitor dabrafenib...
  33. doi request reprint A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors
    David S Hong
    MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 18:4173-82. 2012
    ..The objectives of the study were to evaluate the maximum tolerated dose (MTD), safety, pharmacodynamics, pharmacokinetics, and antitumor activity of PX-866 in patients with incurable cancers...
  34. doi request reprint Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis
    Apostolia M Tsimberidou
    Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Hepatogastroenterology 59:960-4. 2012
    ..We conducted a phase I trial of IP oxaliplatin and paclitaxel with IV paclitaxel and bevacizumab in patients with peritoneal carcinomatosis...
  35. pmc A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies
    John W Moroney
    Department of Gynecology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 17:6840-6. 2011
    ..We, therefore, added temsirolimus (T), which inhibits HIF-1α, to D and A (DAT). Trial objectives were assessment of safety, preliminary efficacy, and identification of biological response correlates...
  36. ncbi request reprint Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors
    David S Hong
    Department of Investigational Cancer Therapeutics Phase I Program, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer 120:2164-73. 2014
    ..The current study was conducted to evaluate the safety and biological activity of dual inhibition of the vascular endothelial growth factor (VEGF) pathway with combined bevacizumab and cediranib (a VEGF receptor tyrosine kinase inhibitor)...
  37. pmc Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases
    Luis H Camacho
    Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Colorectal Cancer 9:311-4. 2010
    ....
  38. pmc FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors
    Denis L Jardim
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 9:e89388. 2014
    ..Preclinical data suggest that FBXW7 mutations sensitize cells to mTOR inhibitors. Clinicopathologic characteristics of cancer patients with FBXW7 mutations and their responses to mTOR inhibitors remain unknown...
  39. pmc Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies
    Gerald S Falchook
    Department of Investigational Cancer Therapeutics Phase I Program, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
    Invest New Drugs 31:1192-200. 2013
    ..Clinical correlates included evaluation of epigenetic changes, methylation patterns, and histone acetylation levels in peripheral blood mononuclear cells...
  40. ncbi request reprint Retreatment after secondary resistance or mixed response: a pilot study
    Aung Naing
    The University of Texas, MD Anderson Cancer Center, Houston, Tex
    Oncology 85:350-5. 2013
    ..Here, we report our findings in a pilot study in patients rechallenged with agents previously producing prolonged stable disease (SD), partial or complete remission (PR/CR) or a mixed response, followed by progression...
  41. doi request reprint Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer
    Prasanth Ganesan
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
    Invest New Drugs 32:279-86. 2014
    ..We conducted a Phase I study of lenalidomide and sorafenib in patients with advanced cancer...
  42. doi request reprint A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies
    Aung Naing
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Invest New Drugs 31:967-73. 2013
    ....
  43. doi request reprint Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations
    Prasanth Ganesan
    Corresponding Author Filip Janku, Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, FC8 2018, Box 0455, Houston, Texas 77030
    Mol Cancer Ther 12:2857-63. 2013
    ..PIK3CA mutations are associated with simultaneous KRAS mutations, possibly accounting for therapeutic resistance...
  44. doi request reprint Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity
    Siqing Fu
    Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 10:1300-7. 2011
    ..HAI nab-paclitaxel showed partial hepatic extraction. At doses 260 mg/m(2) or less given for 1 hour every 3 weeks, the treatment was well-tolerated and showed activity in advanced cancer patients with predominant liver metastases...
  45. doi request reprint Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience
    Aung Naing
    Department of Investigational Cancer Therapeutics Phase 1 Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:5142-50. 2011
    ..Therefore, the concurrent use of complementary and alternative medicine (CAM) in patients with advanced malignancies seen in a dedicated phase 1 clinic was evaluated...
  46. pmc PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors
    Filip Janku
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, FC8 2057, Box 0455, Houston, TX 77030, USA
    Mol Cancer Ther 10:558-65. 2011
    ..5% of patients with diverse solid tumors. The response rate was significantly higher for patients with PIK3CA mutations treated with PI3K/AKT/mTOR pathway inhibitors than for those without documented mutations...
  47. ncbi request reprint Histological features associated with vemurafenib-induced skin toxicities: examination of 141 cutaneous lesions biopsied during therapy
    Jonathan L Curry
    Departments of Pathology, Dermatology, and Atlanta Dermatopathology, Atlanta, GA and Melanoma Medical Oncology, and Investigative Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
    Am J Dermatopathol 36:557-61. 2014
    ..Evaluating the base of the keratinized lesion will aid in distinguishing the histological type of CEP and the management of the DTs; thus, a deep shave or punch biopsy may be warranted for patients who received vemurafenib therapy. ..
  48. pmc Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 0455, Houston, TX 77030, USA
    Target Oncol 8:183-8. 2013
    ..These results suggest that NRAS mutation merits further investigation as a potential biomarker predicting the efficacy of bevacizumab-based treatment...
  49. pmc Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus
    Sarina A Piha-Paul
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, University of Texas MD Anderson Cancer Center, Houston, TX
    Oncotarget 5:1846-55. 2014
    ..Temsirolimus attenuates upregulation of HIF-1α levels, a resistance mechanism for antiangiogenics, and targets the PI3-kinase/AKT/mTOR axis, commonly aberrant in these tumors...
  50. ncbi request reprint Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment
    Ignacio Garrido-Laguna
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, University of Texas M D Anderson Cancer Center, 1515Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 16:4031-7. 2010
    ....
  51. doi request reprint Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases
    Sean S Garcia
    Department of Clinical Sciences and Administration, University of Houston College of Pharmacy, 1441 Moursund St, Houston, TX, 77030, USA
    Cancer Chemother Pharmacol 72:1265-71. 2013
    ..We have observed severe, but rapidly reversible, hyperbilirubinemia in patients receiving hepatic arterial infusion (HAI) of oxaliplatin. We performed a retrospective analysis to characterize this unusual phenomenon...
  52. pmc Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service
    Henrique A Parsons
    Department of Investigational Cancer Therapeutics A Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 7:e29330. 2012
    ..Body weight and body composition are relevant to the outcomes of cancer and antineoplastic therapy. However, their role in Phase I clinical trial patients is unknown...
  53. ncbi request reprint Characteristics and survival of patients with advanced cancer and p53 mutations
    Rabih Said
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX Department of Internal Medicine, Oncology Division, The University of Texas Health Sciences Center, Houston, TX
    Oncotarget 5:3871-9. 2014
    ..15). In conclusion, our results demonstrated resistance to matched-targeted therapy to the other aberrations in patients with p53 mutations and emphasize the need to overcome this resistance. ..
  54. pmc MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
    Denis L Fontes Jardim
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, USA
    Oncotarget 5:1837-45. 2014
    ..In conclusion, MET abnormalities can be found in a small group of patients with GE adenocarcinoma and further studies are necessary to better characterize the prognostic and predictive impact of MET alterations. ..
  55. doi request reprint Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer
    Apostolia Maria Tsimberidou
    Phase I Clinical Trials Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Mol Cancer Ther 9:3410-9. 2010
    ..3 mg/m(2) once weekly for 3 weeks every 28 days was safe in patients with heavily pretreated cancer. Clinical trials with MPC-6827 and chemotherapy are ongoing...
  56. pmc Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors
    Aung Naing
    Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX, 77030, USA
    Invest New Drugs 32:154-9. 2014
    ..TAS-106 was designed to inhibit RNA synthesis by blocking RNA polymerases I, II, and III...
  57. pmc Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit
    Siqing Fu
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Oncologist 18:1315-20. 2013
    ..We conducted this retrospective study to identify reasons that patients referred to a phase I clinical trial failed to enroll or delayed enrollment onto the trial...
  58. ncbi request reprint Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program
    Siqing Fu
    Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 29:3547-52. 2011
    ..This study assessed outcomes of individuals with advanced cancer who required admission to an intensive care unit (ICU) after referral for an early clinical trial because they did not respond to conventional therapy...
  59. doi request reprint A first-in-human study of conatumumab in adult patients with advanced solid tumors
    Roy S Herbst
    Head and Neck Head and Neck Medical Oncology and Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 16:5883-91. 2010
    ..To determine the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of conatumumab, an investigational, fully human monoclonal agonist antibody against human death receptor 5, in patients with advanced solid tumors...
  60. ncbi request reprint A phase I clinical trial of darinaparsin in patients with refractory solid tumors
    Apostolia Maria Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 15:4769-76. 2009
    ..Darinaparsin, an organic arsenic, targets essential cell survival pathways. We determined the dose-limiting toxicity (DLT) and maximum tolerated dose of darinaparsin in patients with advanced cancer...
  61. pmc Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer
    Razelle Kurzrock
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 29:2660-6. 2011
    ..Early observations of clinical benefit in a phase I study of cabozantinib, which included patients with medullary thyroid cancer (MTC), led to expansion of an MTC-enriched cohort, which is the focus of this article...
  62. pmc Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors
    Aung Naing
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:2625-31. 2012
    ..Temsirolimus was combined with cixutumumab, a fully human IgG1 monoclonal antibody directed at the insulin growth factor-1 receptor (IGF-1R)...
  63. pmc Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model
    Jose G Trevino
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Pathol 168:962-72. 2006
    ..These results demonstrate that Src activation contributes to pancreatic tumor progression in this model, offering Src as a candidate for targeted therapy...
  64. ncbi request reprint Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma
    Daniel R Gomez
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77054, USA
    J Thorac Oncol 8:238-45. 2013
    ....
  65. doi request reprint Autophagy as a target for anticancer therapy
    Filip Janku
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Nat Rev Clin Oncol 8:528-39. 2011
    ..To improve our understanding of autophagy in human cancers new methods for measuring autophagy in clinical samples need to be developed. This Review delineates the possible role of autophagy as a novel target for anticancer therapy...
  66. doi request reprint Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs
    Denis L Jardim
    Authors Affiliations Phase I Clinical Trials Program, Department of Investigational Cancer Therapeutics Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas Department of Clinical Medicine, Hemocentro da UNICAMP, University of Campinas, Sao Paulo, Brazil Karmanos Cancer Institute Wayne State University, Detroit, Michigan and Department of Medicine, University of California, San Diego, La Jolla, California
    Clin Cancer Res 20:281-8. 2014
    ..The ability to predict relevant toxicities correlates with the number of patients on the initial phase I trial. The final dose approved was within 20% of the RP2D in 73% of assessed trials...
  67. pmc Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis
    José Luis López Guerra
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Int J Radiat Oncol Biol Phys 84:e61-7. 2012
    ..We investigated prognostic factors associated with survival in patients with non-small cell lung cancer (NSCLC) and oligometastatic disease at diagnosis, particularly the influence of local treatment to the primary site on prognosis...
  68. ncbi request reprint Interleukin-6 and its receptor in cancer: implications for translational therapeutics
    David S Hong
    Phase I Program, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:1911-28. 2007
    ..Therapeutic targeting of IL-6 and its receptor in cancer has strong biologic rationale, and there is preliminary evidence suggesting that targeting of the IL-6 system may be beneficial in the treatment of cancer...
  69. pmc STAT3 inhibitors: finding a home in lymphoma and leukemia
    Javier Munoz
    Hematology Oncology, Banner, MD Anderson Cancer Center, Gilbert, Arizona, USA Hematology Oncology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA Departments of Investigational Cancer Therapeutics Phase I Clinical Trials Program and Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Oncologist 19:536-44. 2014
    ..Targeting the STAT pathway, which seems to be critical in tumorigenesis, is promising for multiple malignancies including lymphoma and leukemia. In this paper, we review mechanisms of action, failures, and successes of STAT3 inhibitors. ..
  70. ncbi request reprint Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions
    Jonathan L Curry
    Department of Pathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA Department of Dermatology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
    Int J Dermatol 53:376-84. 2014
    ..Dermatologic toxicities (DT) to targeted cancer therapy may present as inflammatory dermatoses, keratoses, and as benign and malignant squamous proliferations...
  71. pmc Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience
    Hazem El-Osta
    Department of Investigational Therapeutics, Phase 1 Program Unit 455, Division of Cancer Medicine, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Oncologist 16:1292-8. 2011
    ..Research biopsies are crucial for exploring the impact of novel agents on putative targets. The current study assesses the safety and success rate associated with performing such biopsies...
  72. ncbi request reprint Improving the institutional submission and approval process for clinical research protocols in oncology
    Luis H Camacho
    J Clin Oncol 25:1632-3. 2007